Estimate of posttransplant OS and EFS for the patients who recieved CLAG-M/sorafenib vs CLAG-M alone. Estimates of posttransplantation (A) OS and (B) EFS OS for the 33 patients who received CLAG-M/sorafenib at the RP2D and the 25 medically matched patients who received CLAG-M alone and underwent allogeneic HCT in the first morphologic remission.